Adverse drug events caused by serious medication administration errors

Division of General Medicine and Primary Care, Brigham & Women's Hospital, 3/F 1620 Tremont St, Boston, MA 02120, USA
BMJ quality & safety (Impact Factor: 3.28). 07/2012; 21(11):933-8. DOI: 10.1136/bmjqs-2012-000946
Source: PubMed

ABSTRACT To determine how often serious or life-threatening medication administration errors with the potential to cause harm (potential adverse drug events) result in actual harm (adverse drug events (ADEs)) in the hospital setting.
Retrospective chart review of clinical events following observed medication administration errors.
Medication errors are common at the medication administration stage for inpatients. While many errors can cause harm, it is unclear exactly how often.
In a previous study where 14 041 medication administrations were directly observed, 1271 medication administration errors were discovered, of which 133 had the potential to cause serious or life-threatening harm and were considered serious or life-threatening potential adverse drug events. As a follow-up, clinical reviewers conducted detailed chart review of serious or life-threatening potential ADEs to determine if they caused an ADE. Reviewers assessed severity of the ADE and attribution to the error.
Ten (7.5% (95% CI 6.98 to 8.01)) actual ADEs resulted from the 133 serious and life-threatening potential ADEs, of which 6 resulted in significant, three in serious, and one life threatening injury. Therefore 4 (3% (95% CI 2.12 to 3.6)) of serious or life threatening potential ADEs led to serious or life threatening ADEs. Half of the ADEs were caused by dosage or monitoring errors for anti-hypertensives.
Unintercepted potential ADEs at the medication administration stage can cause serious patient harm. At hospitals where 6 million doses are administered per year, about 4000 preventable ADEs would be attributable to medication administration errors annually.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This IPDMA identifies patient characteristics and types of medication most associated with patients experiencing ADEs and suggests target areas for reducing harm and implement focused interventions.Methods Authors of eligible studies on preventable ADEs (pADEs) were approached for collaboration. For assessment of differences among (non-)surgical patients and identification of associated factors descriptive statistics, Pearson Chi-Square, Poisson and logistic regression analyses were performed. For identification of high risk drugs (HRDs), a model was developed based on frequency, severity and preventability of medication related to ADEs.ResultsIncluded were 5,367 patients from four studies. Patients aged ≥ 77 years experienced more ADEs and pADEs compared to patients aged ≤ 52 years (odds ratios (OR) 2.12 (95%CI 1.70-2.65) and 2.55 (95%CI 1.70-3.84) respectively, both p<0.05). Polypharmacy on admission also increased the risk of ADEs (OR 1.21 (95%CI 1.03-1.44), p<0.05) and pADEs (OR 1.85 (95%CI 1.34-2.56), p < 0.05). pADEs were associated with more severe harm than non-preventable ADEs (54% versus 32%, p < 0.05). The top five HRDs were: antibiotics, sedatives, anticoagulants, diuretics and antihypertensives. Events associated with HRDs included diarrhoea or constipation, abnormal liver function test and central nervous system events. Most pADEs resulted from prescribing errors (90%).Conclusion Elderly patients with polypharmacy on admission and receiving antibiotics, sedatives, anticoagulants, diuretics or antihypertensives were more prone to experiencing ADEs. Efficiency in prevention of ADEs may be improved by targeted vigilance systems for alertness of physicians and pharmacists.
    British Journal of Clinical Pharmacology 09/2014; 79(4). DOI:10.1111/bcp.12504 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimTo compare adverse medication events (AMEs) reported in children, via the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) coding with events reported via other data sources.MethodAME reports were retrieved using codes Y40–Y59 and X40–X44 over 6 months. Patients’ charts were manually reviewed to identify events associated with error and/or harm with medicines during a hospital admission. Medication name, group, error, harm and alert documentation were recorded. Clinical incidents and pharmacist interventions were reviewed for the same period.ResultsTwo hundred sixty-three events from January to June 2011 were recorded by ICD-10 coding in 180 patients. After duplicated, missing or unrelated events were excluded and 146 AMEs remained. In the same period, 117 AMEs were reported as incidents and 190 as pharmacist interventions. In total, 276 children with 447 events were reported via all sources. Little duplication between data sources was evident. In total, 158 events involved harm, with 135 of these from ICD-10 coding, 16 from incident reports and 2 pharmacist interventions (including 6 events from multiple sources). Error was involved in 3% of ICD10 reports, 97% of incidents and 100% of interventions. Only 14% of harm-related events from ICD-10 were documented on the medical record clinical alert. Chemotherapy accounted for 31% of harm-related events, antimicrobials 18%, corticosteroids 14% and narcotics 12%.Conclusion Of the harm-related events, 85% were documented via ICD-10 coding with few documented in other databases. Review of ICD-10-coded AMEs can provide valuable information to improve patient safety and quality.
    Journal of Paediatrics and Child Health 08/2014; 50(12). DOI:10.1111/jpc.12684 · 1.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Harmful medication errors, or preventable adverse drug events (ADEs), are a prominent quality and cost issue in healthcare. Injectable medications are important therapeutic agents, but they are associated with a greater potential for serious harm than oral medications. The national burden of preventable ADEs associated with inpatient injectable medications and the associated medical professional liability (MPL) costs have not been previously described in the literature.
    American Health and Drug Benefits 11/2012; 5(7):1-10.


Available from
May 19, 2014